Groundbreaking cell therapy trial targets devastating lupus kidney damage
NCT ID NCT06342960
Summary
This early-stage study is testing a new, personalized cell therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells thought to drive the disease. The main goals are to check the treatment's safety and see if it can help control the kidney disease and improve patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charite- Universitätsklinikum Berlin
Berlin, Germany
-
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
Frankfurt, Germany
-
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
-
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Conditions
Explore the condition pages connected to this study.